Comparison
Exenatide vs. Liraglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
141758-74-9
204656-20-2
Molecular weight
4186.6 g/mol
3751 g/mol
Half-life
2.4 h
13 h
Sequence
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSHAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGMechanism of action
Exenatide
Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
5
of which in humans
4
4
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
2
1